美国能源部国家实验室不仅可以在科学进步方面发挥不可或缺的作用，而且可以通过在放射性同位素生产设施中进行的研究和开发活动来治疗各种医疗状况。自 2016 年以来，橡树岭国家实验室一直在进行一个项目，其任务是生产和供应放射性同位素 227Ac，该项目用于开发用于治疗某些类型的前列腺癌和骨转移的放射性药物。生产活美国国家标准协会 (ANSI) N13.1-1969 由于其祖父地位。放射性排放量被限制在低于公众年度合规剂量标准的水平，并且 3039 号堆栈将失去其原始地位。为了在不超过相关剂量限值的情况下实现 227Ac 的最大产量，已实施了项目排放量的每月跟踪以及由此产生的 CAP88-PC 模拟最大暴露个体的有效剂量。我们对四年的跟踪数据进行了汇编和分析，以确定可用于更频繁地估算项目剂量的其他方法，从而有可能进一步优化 227Ac 生产，同时保持遵守适用法规。版权所有 © 2024 健康物理学会。

US Department of Energy national laboratories can play an integral role in not only the advancement of science but also in the treatment of various medical conditions through research and development activities conducted at radioisotope production facilities. A project has been underway at Oak Ridge National Laboratory since 2016 whose mission is to produce and supply the radioisotope 227Ac, which is used in a radiopharmaceutical developed to treat certain types of prostate cancer and bone metastases. Production activities result in the environmental release of airborne radioactive emissions, which are governed by Clean Air Act regulations described in 40 CFR Part 61, Subpart H. Stack 3039, the source that emits radioactive effluents from 227Ac production, is subject to additional requirements outlined in American National Standards Institute (ANSI) N13.1-1969 due to its grandfathered status. Radioactive emissions are limited to levels below those that would cause annual compliance dose standards for members of the public to be exceeded and stack 3039 to lose its grandfathered status. To allow for maximum production of 227Ac without exceeding relevant dose limits, monthly tracking of project emissions and resulting CAP88-PC modeled effective doses to a maximally exposed individual have been implemented. Four years of tracking data were compiled and analyzed to identify additional methods that could be used to estimate project doses more frequently, potentially further optimizing 227Ac production while maintaining compliance with applicable regulations.Copyright © 2024 Health Physics Society.